Current pharmacotherapy of overactive bladder in neurological patients

Shvarts P.G.; Vinarov A.Z.; Kadykov A.S.; Borodulina I.V.; Popov S.V.; Kravchenko M.A.

doi:https://doi.org/10.17116/jnevro2014114121152-160

Shvarts P.G.

FGBU "Nauchnyĭ tsentr nevrologii" RAMN, Moskva;
Nauchno-issledovatel'skiĭ institut uronefrologii i reproduktivnogo zdorov'ia cheloveka, Moskva

Vinarov A.Z.

Nauchno-issledovatel'skiĭ institut uronefrologii i reproduktivnogo zdorov'ia cheloveka, Moskva;
GBOU VPO "Pervyĭ moskovskiĭ gosudarstvennyĭ meditsinskiĭ universitet im. I.M. Sechenova", Moskva

Kadykov A.S.

FGBU "Nauchnyĭ tsentr nevrologii" RAMN, Moskva

Borodulina I.V.

National Medical Research Center of Rehabilitation and Balneology of the Ministry of Health Care of the Russia, Moscow, Russia

SPIN RSCI: 2152-5737
ORCID: 0000-0001-7526-1553

Popov S.V.

FGBU "Nauchnyĭ tsentr nevrologii" RAMN, Moskva

Kravchenko M.A.

FGBU "Nauchnyĭ tsentr nevrologii" RAMN, Moskva

Current pharmacotherapy of overactive bladder in neurological patients

Authors:

Shvarts P.G., Vinarov A.Z., Kadykov A.S., Borodulina I.V., Popov S.V., Kravchenko M.A.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2014;114(12): 152‑160

DOI: 10.17116/jnevro2014114121152-160

Read: 13086 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Shvarts PG, Vinarov AZ, Kadykov AS, Borodulina IV, Popov SV, Kravchenko MA. Current pharmacotherapy of overactive bladder in neurological patients. S.S. Korsakov Journal of Neurology and Psychiatry. 2014;114(12):152‑160. (In Russ.)
https://doi.org/10.17116/jnevro2014114121152-160

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)

Использование инфографики авторами научных работ

Close metadata

Abstract:

The literature data on the urgent neurological problem - overactive bladder (OAB) are summarized. The OAB prevalence, current conceptions on the physiology and pathophysiology of urination and pathogenetic mechanisms of OAB development are presented. Main groups of pharmacological agents used in OAB treatment are described. Special attention is drawn to rationale of using anticholinergic (antimuscarinic) drugs. The authors present the results of their own comparative analysis on the efficacy and tolerability of these drugs in treatment of patients with cerebral vascular diseases including the use of solifenacin succinate (VESIcare).

Keywords:

overactive bladder

cerebral vascular diseases

anticholinergic drugs

solifenacin succinate

Authors:

Shvarts P.G.

FGBU "Nauchnyĭ tsentr nevrologii" RAMN, Moskva;
Nauchno-issledovatel'skiĭ institut uronefrologii i reproduktivnogo zdorov'ia cheloveka, Moskva

Vinarov A.Z.

Nauchno-issledovatel'skiĭ institut uronefrologii i reproduktivnogo zdorov'ia cheloveka, Moskva;
GBOU VPO "Pervyĭ moskovskiĭ gosudarstvennyĭ meditsinskiĭ universitet im. I.M. Sechenova", Moskva

Kadykov A.S.

FGBU "Nauchnyĭ tsentr nevrologii" RAMN, Moskva

Borodulina I.V.

National Medical Research Center of Rehabilitation and Balneology of the Ministry of Health Care of the Russia, Moscow, Russia

SPIN RSCI: 2152-5737
ORCID: 0000-0001-7526-1553

Popov S.V.

FGBU "Nauchnyĭ tsentr nevrologii" RAMN, Moskva

Kravchenko M.A.

FGBU "Nauchnyĭ tsentr nevrologii" RAMN, Moskva

Close metadata

References:

Shvarts G.Ya. i dr. Lekarstvennye sredstva dlya lecheniya sindroma giperaktivnogo mochevogo puzyrya: nastoyashchee i budushchee. Khimiko-farmatsevticheskii zhurnal 2012; 12: 95-102.
Pushkar' D.Yu. Giperaktivnyi mochevoi puzyr' u zhenshchin. M: MEDpress-inform 2003; 159.
Neirogennye disfunktsii mochevogo puzyrya. Pod red. M.D. Dzhavadzade, V.M. Derzhavina. M: Meditsina 1989; 384.
Rasseyannyi skleroz. Izbrannye voprosy teorii i praktiki. Pod red. I.A. Zavalishina, V.I. Golovkina. M 2000; 625.
Savchenko N.E., Mokhort V.A. Neirogennye rasstroistva mocheispuskaniya. Minsk: Belorus' 1970; 244.
Araki I., Kuno S. Assessment of voiding dysfunction in Parkinson's disease by the international prostate symptom score. J Neurol Neurosurg Psychiatry 2000; 68: 4: 429-433.
Langhorne P. Medical complication after stroke. Stroke 2000; 31: 6: 1223-1229.
Shvarts P.G. Diagnostika neirogennykh narushenii mocheispuskaniya. Rus med zhurn 2011; 32: 2063-2067.
Al'-Shukri S.Kh., Kuz'min I.V. Giperaktivnost' detruzora i urgentnoe nederzhanie mochi. Posobie dlya vrachei. SPb 1999; 48.
Mazo E.B., Krivoborodov G.G., Shkol'nikov M.E. Neirogennyi giperaktivnyi mochevoi puzyr'. Trudnyi patsient 2004; 6: 1-7.
Ohtake A. Pharmacological Characterization of a New Antimuscarinic Agent, Solifenacin Succinate, in Comparison with Other Antimuscarinic Agents. Biol Pharm Bull 2008; 30: 1: 54-58.
Shvarts P.G. Fenomenologiya neirogennykh narushenii mocheispuskaniya. Rus med zhurn 2012; 18: 912-916.
Abrams P.H., Blaivas J.G., Stanton S.L., Anderson J.T. Standartization of terminology of lower urinary tract function. Neurourol Urodyn 1988; 7: 403-428.